Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action
This article was originally published in The Tan Sheet
Executive Summary
A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt
You may also be interested in...
As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream
Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices
As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream
Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices
As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream
Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices